GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » EBITDA Margin %

PCI Biotech Holding ASA (OSL:PCIB) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. PCI Biotech Holding ASA's EBITDA for the six months ended in Dec. 2024 was kr-8.80 Mil. PCI Biotech Holding ASA's Revenue for the six months ended in Dec. 2024 was kr0.00 Mil. Therefore, PCI Biotech Holding ASA's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


PCI Biotech Holding ASA EBITDA Margin % Historical Data

The historical data trend for PCI Biotech Holding ASA's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA EBITDA Margin % Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PCI Biotech Holding ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PCI Biotech Holding ASA's EBITDA Margin %

For the Biotechnology subindustry, PCI Biotech Holding ASA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's EBITDA Margin % falls into.


;
;

PCI Biotech Holding ASA EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

PCI Biotech Holding ASA's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-16.055/0
= %

PCI Biotech Holding ASA's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-8.801/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (OSL:PCIB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


PCI Biotech Holding ASA EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines